igfbp 1

Insulin-like growth factor-binding protein 1 (IGFBP1) is encoded by 259 amino acid (aa) with 25 aa residue signal peptide that is processed to generate the 234 aa residue mature protein. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Promotes cell migration. Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).

Expression system: E. coli
Length: 26-272, Full Length of Mature Protein
Activity: Not Tested

Expression system: E. coli
Length: 26-272, Full Length of Mature Protein
Activity: Not Tested

IGFBP-7 Protein, Mouse, Recombinant (aa 1-281, hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 53.3 kDa and the accession number is A0A5E1.

Expression system: HEK293 Cells
Length: 1-282, Full Length
Activity: ELISA

IGFBP-1 Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26 kDa and the accession number is A0A8C0MZD6.

IGFBP-1 Protein, Mouse, Recombinant (His) is expressed in Mammalian cell. The accession number is P47876.

IGFBP-1 Protein, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.7 kDa and the accession number is A0A1D5QTL3.

Expression system: HEK293 Cells
Length: 1-282, Full Length
Activity: Not Tested

Expression system: HEK293 Cells
Length: 26-354, Partial
Activity: Not Tested

Expression system: HEK293 Cells
Length: 30-282, Partial
Activity: ELISA

Expression system: HEK293 Cells
Length: 1-282, Full Length
Activity: ELISA

Insulin-like growth factor 2 (IGF-2 IGF-II) is a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumor, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. IGF-2 IGF-II is a mediator of prolactin-induced alveologenesis; prolactin, IGF-2, and cyclin D1, all of which are overexpressed in breast cancers, are components of a developmental pathway in the mammary gland. IGF-2 and exhibited statistically significant, positive associations with colorectal cancer risk when cases were confined to those diagnosed within a relatively short period after enrolment. Circulating IGF-2 and IGFBP-3 can serve as early indicators of impending colorectal cancer. IGF-2 IGF-II appears to be involved in the progression of many tumors. It binds to at least two different types of receptors: IGF type 1 (IGF 1R) and mannose 6-phosphate IGF type 2 (M6-P IGF 2R). Ligand binding to IGF 1R provokes mitogenic and anti-apoptotic effects. M6-P IGF 2R has a tumor suppressor function—it mediates IGF 2 degradation. Mutation of M6-P IGF 2R causes both diminished growth suppression and augmented growth stimulation. This study aimed to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R) in human gastric cancer.

Mouse Insulin-like growth factor-binding protein 5(IGFBP-5) belongs to the superfamily of insulin-like growth factor (IGF) binding proteins. It contains 1 IGFBP N-terminal domain and 1 thyroglobulin type-1 domain. Mouse IGFBP-5 shows 97% aa sequence identity with those of human and rat IGFBP-5. It is expressed mostly in kidney, uterus and gastrocnemius muscle. It also expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts. IGFBP-5 has a strong affinity for hydroxyapatite, allowing it to bind to bone cells. When bound to extracelluar matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21 kDa fragment. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.

Expression system: Baculovirus Insect Cells
Length: 1-272, Full Length
Activity: Cell Activity

Expression system: HEK293 Cells
Length: 30-282, Partial
Activity: Not Tested

Expression system: HEK293 Cells
Length: 21-272, Full Length of Mature Protein
Activity: Not Tested

Expression system: HEK293 Cells
Length: 26-281, Full Length
Activity: SPR

Expression system: E. coli
Length: 25-381, Full Length of Mature Protein
Activity: Not Tested

Expression system: E. coli
Length: 25-381, Full Length of Mature Protein
Activity: Cell Activity

Expression system: E. coli
Length: 25-379, Full Length of Mature Protein
Activity: Not Tested

Expression system: HEK293 Cells
Length: 30-282, Partial
Activity: ELISA

CCN4 Wnt-induced secreted protein 1 (WISP1) is a secreted, cysteine-rich, heparin-binding glycoprotein, belonging to the CCN (CTGF CYR61 NOV) family of growth factors, and is involved in diverse biological functions such as cell growth, adhesion, migration, angiogenesis, tissue repair, and regulation of extracellular matrix. Members of the CCN family demonstrate high structural homology sharing four conserved cysteine-rich modular domains: an IGFBP (insulin-like growth factor-binding) domain, a von Willebrand type C domain, a thrombospondin domain and a C-terminal cysteine -knot domain. WISP1 is a putative downstream effector of the Wnt Frizzled pathway that mediates diverse developmental processes, was identified as an oncogene regulated by the Wnt-1-beta-catenin pathway. Thus WISP1 may contribute to Wnt-1-mediated tumorigenesis and malignance. Expression of WISP1 in some cells results in transformation and tumorigenesis. WISP1 acts to block cell death at a late stage in the p53-mediated apoptosis pathway. It was reported that WISP1 interacts with sulfated glycoconjugates, decorin and biglycan in the ECM of connective tissue, and possibly prevents their inhibitory activity in tumor cell proliferation.

IGFBP-7, also known as Mac25 Angiomodulin (AGM), GFBP-rp1, tumor-derived adhesion factor (TAF) and prostacyclin-stimulating factor (PSF), is a secreted protein that contains three protein domain modules. Human IGFBP-rp1 cDNA encodes 282 amino acid (aa) residue precursor protein with a putative 26 aa signal peptide. IGFBP-7 binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion. IGFBP-7 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 53.20 kDa and the accession number is IGFBP-7.